Immunologic considerations of carcinoma of the prostate.
D000017:ABO Blood-Group System; D000906:Antibodies / Q000032:analysis; D000974:Antibodies, Antinuclear / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D001659:Biliary Tract / Q000276:immunology; D001666:Binding Sites, Antibody; D001798:Blood Proteins; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003165:Complement System Proteins / Q000032:analysis; D006801:Humans; D006968:Hypersensitivity, Delayed; D005779:Immunodiffusion; D007136:Immunoglobulins / Q000032:analysis; D007167:Immunotherapy; D007519:Isoantigens / Q000032:analysis; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D011467:Prostate / Q000276:immunology; D011471:Prostatic Neoplasms / Q000097:blood / Q000276:immunology* / Q000628:therapy
D000017:ABO Blood-Group System; D000906:Antibodies; D000974:Antibodies, Antinuclear; D000951:Antigens, Neoplasm; D001798:Blood Proteins; D002272:Carcinoembryonic Antigen; D007136:Immunoglobulins; D007519:Isoantigens; D003165:Complement System Proteins